Alnylam Pharmaceuticals (ALNY) PT Set at $151.00 by Credit Suisse Group
Credit Suisse Group set a $151.00 target price on Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report report published on Friday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other equities analysts have also recently weighed in on the stock. Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a buy rating to a conviction-buy rating in a research report on Friday, December 15th. Piper Jaffray Companies reissued a buy rating and set a $182.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 17th. B. Riley reduced their price target on shares of Alnylam Pharmaceuticals to $220.00 and set a buy rating on the stock in a research report on Wednesday, November 8th. Morgan Stanley lifted their price target on shares of Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the stock an equal weight rating in a research report on Thursday, November 9th. Finally, BidaskClub cut shares of Alnylam Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, December 7th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Alnylam Pharmaceuticals has an average rating of Buy and an average price target of $126.98.
Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $117.30 on Friday. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals has a fifty-two week low of $44.50 and a fifty-two week high of $147.63. The company has a market cap of $11,530.00, a price-to-earnings ratio of -21.68 and a beta of 2.68.
In related news, CEO John Maraganore sold 74,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total value of $9,387,640.00. Following the sale, the chief executive officer now directly owns 223,710 shares of the company’s stock, valued at approximately $28,379,850.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Laurie Keating sold 6,249 shares of the business’s stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total transaction of $757,378.80. Following the completion of the sale, the senior vice president now directly owns 17,749 shares in the company, valued at $2,151,178.80. The disclosure for this sale can be found here. Insiders sold a total of 220,409 shares of company stock worth $28,667,017 over the last ninety days. 4.30% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of ALNY. Northern Trust Corp lifted its position in Alnylam Pharmaceuticals by 5.0% during the 2nd quarter. Northern Trust Corp now owns 377,020 shares of the biopharmaceutical company’s stock worth $30,072,000 after buying an additional 17,862 shares in the last quarter. Suntrust Banks Inc. bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $320,000. Parametric Portfolio Associates LLC lifted its position in Alnylam Pharmaceuticals by 8.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 64,943 shares of the biopharmaceutical company’s stock worth $5,180,000 after buying an additional 4,913 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Alnylam Pharmaceuticals by 59.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 179,429 shares of the biopharmaceutical company’s stock worth $14,311,000 after buying an additional 66,651 shares in the last quarter. Finally, QS Investors LLC lifted its position in Alnylam Pharmaceuticals by 59.7% during the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 900 shares in the last quarter. 88.59% of the stock is currently owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.